SCYNEXIS to Participate in Upcoming January Investor Conferences
01/06/2022 - 01:03 PM
JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.
Presentation details:
LifeSci Partners 11 th Annual Corporate Access Event Format: Virtual panel discussion with CEO and 1:1 meetingsPanel Title: The Best of Both Worlds – Defining Yourself When You Fit into More Than One BasketDate and Time: Friday, January 7, at 10:00 a.m. ETRegistration link: LifeSci Partners Corporate Access Event 2022 H.C. Wainwright Bioconnect 2022 Virtual Healthcare Conference Format: Virtual event with webcast of corporate update presentation by Dr. TagliettiDate and Time: Presentation webcast will be available on-demand January 10-13 for event participantsRegistration link: H.C. Wainwright Bioconnect 2022 The latest SCYNEXIS investor presentation can be found on the corporate website here .
About SCYNEXIS ® (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. For more information, visit www.brexafemme.com . We are also continuing late-stage clinical development of ibrexafungerp for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients. For more information, visit www.scynexis.com .
CONTACT : Investor Relations ikoffler@lifesciadvisors.com
Media Relations ggasaatura@lifescicomms.com
SCYX Rankings
#3676 Ranked by Stock Gains
SCYX Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Jersey City
About SCYX
scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.
